On November 14, 2017 Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) reported that it has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar (clofarabine) Injection in the United States market, approved by the U.S. Food & Drug Administration (USFDA) (Press release, Dr Reddy’s, NOV 14, 2017, View Source [SID1234522026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Clolar brand and generic had U.S. sales of approximately $53 million MAT* for the most recent twelve months ended in September 2017, according to IMS Health*.

Dr. Reddy’s Laboratories’ Clofarabine Injection is available in single-dose, 20 mL flint vials containing 20 mg of clofarabine in 20 mL of solution (1mg/mL).

Clolar is a registered trademark of Genzyme Corporation.

*IMS National Sales Perspective: Retail and Non-Retail MAT September 2017
RDY-0217-146